Background Early and non-invasive detection of platelets on micro atherothrombosis provides a means to identify unstable plaque and thereby allowing prophylactic treatment towards prevention of stroke or myocardial infarction. Molecular magnetic resonance imaging (mMRI) of activated platelets as early markers of plaque rupture using targeted contrast agents is a promising strategy. In this study, we aim to specifically image activated platelets in murine atherothrombosis by in vivo mMRI, using a dedicated animal model of plaque rupture. Methods An antibody targeting ligand-induced binding sites (LIBS) on the glycoprotein IIb/IIIa-receptor of activated platelets was conjugated to microparticles of iron oxide (MPIO) to form the LIBS-MPIO contrast agent causing a signal-extinction in T2*-weighted MRI. ApoE？/？ mice (60 weeks-old) were fed a high fat diet for 5 weeks. Using a small needle, the surface of their carotid plaques was scratched under blood flow to induce atherothrombosis. In vivo 9.4 Tesla MRI was performed before and repetitively after intravenous injection of either LIBS-MPIO versus non-targeted-MPIO. Results LIBS-MPIO injected animals showed a significant signal extinction (p<0.05) in MRI, corresponding to the site of plaque rupture and atherothrombosis in histology. The signal attenuation was effective for atherothrombosis occupying ≥2% of the vascular lumen. Histology further confirmed significant binding of LIBS-MPIO compared to control-MPIO on the thrombus developing on the surface of ruptured plaques (p<0.01). Conclusion in vivo mMRI detected activated platelets on mechanically ruptured atherosclerotic plaques in ApoE？/？ mice with a high sensititvity. This imaging technology represents a unique opportunity for noninvasive detection of atherothrombosis and the identification of unstable atherosclerotic plaques with the ultimate promise to prevent strokes and myocardial infarctions.
References
[1]
Corti R, Farkouh ME, Badimon JJ (2002) The vulnerable plaque and acute coronary syndromes. Am J Med 113: 668–680.
[2]
Gross S, Tilly P, Hentsch D, Vonesch JL, Fabre JE (2007) Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J Exp Med 204: 311–320.
[3]
Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, et al. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal 32: 2999–3054.
[4]
Stone GW, Maehara A, Lansky AJ, de BB, Cristea E, et al. (2011) A prospective natural-history study of coronary atherosclerosis. N Engl J Med 364: 226–235.
[5]
Rogers IS, Nasir K, Figueroa AL, Cury RC, Hoffmann U, et al. (2010) Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging 3: 388–397.
[6]
Choudhury RP, Fisher EA (2009) Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol 29: 983–991.
[7]
Rogers WJ, Prichard JW, Hu YL, Olson PR, Benckart DH, et al. (2000) Characterization of signal properties in atherosclerotic plaque components by intravascular MRI. Arterioscler Thromb Vasc Biol 20: 1824–1830.
[8]
Choudhury RP, Fuster V, Fayad ZA (2004) Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov 3: 913–925.
[9]
von zur Muhlen C, von Elverfeldt D, Moeller JA, Choudhury RP, Paul D, et al. (2008) Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation 118: 258–267.
[10]
von zur Muhlen C, von ED, Choudhury RP, Ender J, Ahrens I, et al. (2008) Functionalized magnetic resonance contrast agent selectively binds to glycoprotein IIb/IIIa on activated human platelets under flow conditions and is detectable at clinically relevant field strengths. Mol Imaging 7: 59–67.
[11]
von zur Muhlen C, Sibson NR, Peter K, Campbell SJ, Wilainam P, et al. (2008) A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. J Clin Invest 118: 1198–1207.
[12]
von zur Muhlen C, Peter K, Ali ZA, Schneider JE, McAteer MA, et al. (2009) Visualization of activated platelets by targeted magnetic resonance imaging utilizing conformation-specific antibodies against glycoprotein IIb/IIIa. J Vasc Res 46: 6–14.
[13]
Schwarz M, Katagiri Y, Kotani M, Bassler N, Loeffler C, et al. (2004) Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61). J Pharmacol Exp Ther 308: 1002–1011.
[14]
Stoll P, Bassler N, Hagemeyer CE, Eisenhardt SU, Chen YC, et al. (2007) Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler Thromb Vasc Biol 27: 1206–1212.
[15]
Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, et al. (2006) Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res 99: 25–33.
[16]
Getz GS, Reardon CA (2006) Diet and Murine Atherosclerosis. Arterioscler Thromb Vasc Biol 26: 242–249.
[17]
Shapiro EM, Skrtic S, Koretsky AP (2005) Sizing it up: cellular MRI using micron-sized iron oxide particles. Magn Reson Med 53: 329–338.
[18]
Shapiro EM, Sharer K, Skrtic S, Koretsky AP (2006) In vivo detection of single cells by MRI. Magn Reson Med 55: 242–249.
[19]
Gawaz M, Langer H, May AE (2005) Platelets in inflammation and atherogenesis. J Clin Invest 115: 3378–3384.
[20]
Gawaz M (2004) Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 61: 498–511.
[21]
Langer HF, Haubner R, Pichler BJ, Gawaz M (2008) Radionuclide imaging: a molecular key to the atherosclerotic plaque. J Am Coll Cardiol 52: 1–12.
[22]
Jansen CH, Perera D, Makowski MR, Wiethoff AJ, Phinikaridou A, et al. (2011) Detection of intracoronary thrombus by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 124: 416–424.
[23]
Sirol M, Aguinaldo JG, Graham PB, Weisskoff R, Lauffer R, et al. (2005) Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. Atherosclerosis 182: 79–85.
[24]
Sirol M, Fuster V, Badimon JJ, Fallon JT, Moreno PR, et al. (2005) Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation 112: 1594–1600.
[25]
Klink A, Lancelot E, Ballet S, Vucic E, Fabre JE, et al. (2010) Magnetic resonance molecular imaging of thrombosis in an arachidonic acid mouse model using an activated platelet targeted probe. Arterioscler Thromb Vasc Biol 30: 403–410.
[26]
Gawaz M, Konrad I, Hauser AI, Sauer S, Li Z, et al. (2005) Non-invasive imaging of glycoprotein VI binding to injured arterial lesions. Thromb Haemost 93: 910–913.
[27]
Bigalke B, Lindemann S, Sch+？nberger T, Pohlmeyer I, Chiribiri A, et al. (2011) Ex vivoimaging of injured arteries in rabbits using fluorescence-labelled glycoprotein VI-Fc. Platelets 23: 1–6.
[28]
Dharmakumar R, Koktzoglou I, Li D (2006) Generating positive contrast from off-resonant spins with steady-state free precession magnetic resonance imaging: theory and proof-of-principle experiments. Phys Med Biol 51: 4201–4215.
[29]
Patil S, Jirak D, Saudek F, Hajek M, Scheffler K (2011) Positive contrast visualization of SPIO-labeled pancreatic islets using echo-dephased steady-state free precession. Eur Radiol 21: 214–220.
[30]
Weizenecker J, Gleich B, Rahmer J, Dahnke H, Borgert J (2009) Three-dimensional real-time in vivo magnetic particle imaging. Phys Med Biol 54: L1–L10.
